Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: HEPATITIS C, CHRONIC - DRUG THERAPY , . Treffer: 43

2019

Chaillon, A; Mehta, SR; Hoenigl, M; Solomon, SS; Vickerman, P; Hickman, M; Skaathun, B; Martin, NK Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
PLoS One. 2019; 14(6):e0217964-e0217964 Doi: 10.1371/journal.pone.0217964 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Indolfi, G; Hierro, L; Dezsofi, A; Jahnel, J; Debray, D; Hadzic, N; Czubkowski, P; Gupte, G; Mozer-Glassberg, Y; van der Woerd, W; Smets, F; Verkade, HJ; Fischler, B Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
J Pediatr Gastroenterol Nutr. 2018; 66(3):505-515 Doi: 10.1097/MPG.0000000000001872
Web of Science PubMed FullText FullText_MUG

 

Korda, D; Lenard, ZM; Gerlei, Z; Jakab, Z; Haboub-Sandil, A; Wagner, L; Varga, M; Cseprekal, O; Marton, A; Horvathy, D; Takacs, S; Doros, A; Mathe, Z Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
Eur J Gastroenterol Hepatol. 2018; 30(1):27-32 Doi: 10.1097/MEG.0000000000001003
Web of Science PubMed FullText FullText_MUG

 

2017

Stauber, RE; Fauler, G; Rainer, F; Leber, B; Posch, A; Streit, A; Spindelboeck, W; Stadlbauer, V; Kessler, HH; Mangge, H Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus.
Wien Klin Wochenschr. 2017; 129(21-22):848-851 Doi: 10.1007/s00508-017-1268-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Beinhardt, S; Al Zoairy, R; Ferenci, P; Kozbial, K; Freissmuth, C; Stern, R; Stättermayer, AF; Stauber, R; Strasser, M; Zoller, H; Watschinger, B; Schmidt, A; Trauner, M; Hofer, H; Maieron, A DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Transpl Int. 2016; 29(9):999-1007 Doi: 10.1111/tri.12799 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fontana, RJ; Brown, RS; Moreno-Zamora, A; Prieto, M; Joshi, S; Londoño, MC; Herzer, K; Chacko, KR; Stauber, RE; Knop, V; Jafri, SM; Castells, L; Ferenci, P; Torti, C; Durand, CM; Loiacono, L; Lionetti, R; Bahirwani, R; Weiland, O; Mubarak, A; ElSharkawy, AM; Stadler, B; Montalbano, M; Berg, C; Pellicelli, AM; Stenmark, S; Vekeman, F; Ionescu-Ittu, R; Emond, B; Reddy, KR Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Liver Transpl. 2016; 22(4):446-458 Doi: 10.1002/lt.24416 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Spindelboeck, W; Horvath, A; Tawdrous, M; Schmerböck, B; Zettel, G; Posch, A; Streit, A; Jurse, P; Lemesch, S; Horn, M; Wuensch, G; Stiegler, P; Stauber, RE; Leber, B; Stadlbauer, V Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
PLoS One. 2016; 11(3):e0150299-e0150299 Doi: 10.1371/journal.pone.0150299 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stern, R; Hametner, S; Ramona, AZ; Moser, S; Karpi, A; Laferl, H; Stauber, RE; Zoller, HM; Maieron, A; Vogel, W; Graziadei, I; Gschwantler, M; Kozbial, K; Freissmuth, C; Hofer, H; Ferenci, P Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Am J Gastroenterol. 2016; 111(5):744-745 Doi: 10.1038/ajg.2016.39
Web of Science PubMed FullText FullText_MUG

 

2015

Baranyi, A; Meinitzer, A; Breitenecker, RJ; Amouzadeh-Ghadikolai, O; Stauber, R; Rothenhäusler, HB Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis.
PLoS One. 2015; 10(9):e0137022-e0137022 Doi: 10.1371/journal.pone.0137022 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mandorfer, M; Steiner, S; Schwabl, P; Payer, BA; Aichelburg, MC; Lang, G; Grabmeier-Pfistershammer, K; Trauner, M; Peck-Radosavljevic, M; Reiberger, T Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
J Infect Dis. 2015; 211(5):729-735 Doi: 10.1093/infdis/jiu516 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rutter, K; Stättermayer, AF; Beinhardt, S; Scherzer, TM; Steindl-Munda, P; Trauner, M; Ferenci, P; Hofer, H Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.
Aliment Pharmacol Ther. 2015; 41(6):521-531 Doi: 10.1111/apt.13085 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Baranyi, A; Meinitzer, A; Putz-Bankuti, C; Stauber, R; Kapfhammer, HP; Rothenhäusler, HB Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
Psychosom Med. 2014; 76(3):197-207 Doi: 10.1097/PSY.0000000000000042
Web of Science PubMed FullText FullText_MUG

 

Mandorfer, M; Payer, BA; Niederecker, A; Lang, G; Aichelburg, MC; Strassl, R; Boesecke, C; Rieger, A; Trauner, M; Peck-Radosavljevic, M; Reiberger, T Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
AIDS Patient Care STDS. 2014; 28(5): 221-227. Doi: 10.1089/apc.2013.0359
Web of Science PubMed FullText FullText_MUG

 

Mandorfer, M; Reiberger, T; Payer, BA; Breitenecker, F; Aichelburg, MC; Obermayer-Pietsch, B; Rieger, A; Puoti, M; Zangerle, R; Trauner, M; Peck-Radosavljevic, M Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.
J Viral Hepat. 2014; 21(1):33-41 Doi: 10.1111/jvh.12118
Web of Science PubMed FullText FullText_MUG

 

Razavi, H; Waked, I; Sarrazin, C; Myers, RP; Idilman, R; Calinas, F; Vogel, W; Mendes Correa, MC; Hézode, C; Lázaro, P; Akarca, U; Aleman, S; Balık, I; Berg, T; Bihl, F; Bilodeau, M; Blasco, AJ; Brandão Mello, CE; Bruggmann, P; Buti, M; Calleja, JL; Cheinquer, H; Christensen, PB; Clausen, M; Coelho, HS; Cramp, ME; Dore, GJ; Doss, W; Duberg, AS; El-Sayed, MH; Ergör, G; Esmat, G; Falconer, K; Félix, J; Ferraz, ML; Ferreira, PR; Frankova, S; García-Samaniego, J; Gerstoft, J; Giria, JA; Gonçales, FL; Gower, E; Gschwantler, M; Guimarães Pessôa, M; Hindman, SJ; Hofer, H; Husa, P; Kåberg, M; Kaita, KD; Kautz, A; Kaymakoglu, S; Krajden, M; Krarup, H; Laleman, W; Lavanchy, D; Marinho, RT; Marotta, P; Mauss, S; Moreno, C; Murphy, K; Negro, F; Nemecek, V; Örmeci, N; Øvrehus, AL; Parkes, J; Pasini, K; Peltekian, KM; Ramji, A; Reis, N; Roberts, SK; Rosenberg, WM; Roudot-Thoraval, F; Ryder, SD; Sarmento-Castro, R; Semela, D; Sherman, M; Shiha, GE; Sievert, W; Sperl, J; Stärkel, P; Stauber, RE; Thompson, AJ; Urbanek, P; Van Damme, P; van Thiel, I; Van Vlierberghe, H; Vandijck, D; Wedemeyer, H; Weis, N; Wiegand, J; Yosry, A; Zekry, A; Cornberg, M; Müllhaupt, B; Estes, C The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
J Viral Hepat. 2014; 21 Suppl 1(41):34-59 Doi: 10.1111/jvh.12248 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stättermayer, AF; Rutter, K; Beinhardt, S; Wrba, F; Scherzer, TM; Strasser, M; Hofer, H; Steindl-Munda, P; Trauner, M; Ferenci, P Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Liver Int. 2014; 34(3): 388-395. Doi: 10.1111/liv.12269
Web of Science PubMed FullText FullText_MUG

 

Stättermayer, AF; Strassl, R; Maieron, A; Rutter, K; Stauber, R; Strasser, M; Beinhardt, S; Datz, C; Scherzer, TM; Steindl-Munda, P; Gschwantler, M; Trauner, M; Hofer, H; Ferenci, P Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Aliment Pharmacol Ther. 2014; 39(1):104-111 Doi: 10.1111/apt.12547 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wedemeyer, H; Duberg, AS; Buti, M; Rosenberg, WM; Frankova, S; Esmat, G; Örmeci, N; Van Vlierberghe, H; Gschwantler, M; Akarca, U; Aleman, S; Balık, I; Berg, T; Bihl, F; Bilodeau, M; Blasco, AJ; Brandão Mello, CE; Bruggmann, P; Calinas, F; Calleja, JL; Cheinquer, H; Christensen, PB; Clausen, M; Coelho, HS; Cornberg, M; Cramp, ME; Dore, GJ; Doss, W; El-Sayed, MH; Ergör, G; Estes, C; Falconer, K; Félix, J; Ferraz, ML; Ferreira, PR; García-Samaniego, J; Gerstoft, J; Giria, JA; Gonçales, FL; Guimarães Pessôa, M; Hézode, C; Hindman, SJ; Hofer, H; Husa, P; Idilman, R; Kåberg, M; Kaita, KD; Kautz, A; Kaymakoglu, S; Krajden, M; Krarup, H; Laleman, W; Lavanchy, D; Lázaro, P; Marinho, RT; Marotta, P; Mauss, S; Mendes Correa, MC; Moreno, C; Müllhaupt, B; Myers, RP; Nemecek, V; Øvrehus, AL; Parkes, J; Peltekian, KM; Ramji, A; Razavi, H; Reis, N; Roberts, SK; Roudot-Thoraval, F; Ryder, SD; Sarmento-Castro, R; Sarrazin, C; Semela, D; Sherman, M; Shiha, GE; Sperl, J; Stärkel, P; Stauber, RE; Thompson, AJ; Urbanek, P; Van Damme, P; van Thiel, I; Vandijck, D; Vogel, W; Waked, I; Weis, N; Wiegand, J; Yosry, A; Zekry, A; Negro, F; Sievert, W; Gower, E Strategies to manage hepatitis C virus (HCV) disease burden.
J Viral Hepat. 2014; 21 Suppl 1(41):60-89 Doi: 10.1111/jvh.12249 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Baranyi, A; Meinitzer, A; Stepan, A; Putz-Bankuti, C; Breitenecker, RJ; Stauber, R; Kapfhammer, HP; Rothenhäusler, HB A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection.
Psychother Psychosom. 2013; 82(5):332-340 Doi: 10.1159/000348587
Web of Science PubMed FullText FullText_MUG

 

Esser-Nobis, K; Romero-Brey, I; Ganten, TM; Gouttenoire, J; Harak, C; Klein, R; Schemmer, P; Binder, M; Schnitzler, P; Moradpour, D; Bartenschlager, R; Polyak, SJ; Stremmel, W; Penin, F; Eisenbach, C; Lohmann, V Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Hepatology. 2013; 57(3):953-963 Doi: 10.1002/hep.26260 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mandorfer, M; Neukam, K; Reiberger, T; Payer, BA; Rivero, A; Puoti, M; Boesecke, C; Baumgarten, A; Grzeszczuk, A; Zangerle, R; Meyer-Olson, D; Rockstroh, JK; Trauner, M; Pineda, JA; Peck-Radosavljevic, M The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
AIDS. 2013; 27(17): 2707-2714. Doi: 10.1097/01.aids.0000432460.44593.ef
Web of Science PubMed FullText FullText_MUG

 

Scherzer, TM; Stättermayer, AF; Stauber, R; Maieron, A; Strasser, M; Laferl, H; Schwarzer, R; Datz, C; Rutter, K; Beinhardt, S; Steindl-Munda, P; Hofer, H; Ferenci, P Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
J Hepatol. 2013; 59(5):964-971 Doi: 10.1016/j.jhep.2013.06.030
Web of Science PubMed FullText FullText_MUG

 

2011

Reiberger, T; Rutter, K; Ferlitsch, A; Payer, BA; Hofer, H; Beinhardt, S; Kundi, M; Ferenci, P; Gangl, A; Trauner, M; Peck-Radosavljevic, M Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Clin Gastroenterol Hepatol. 2011; 9(7):602-608 Doi: 10.1016/j.cgh.2011.03.002
Web of Science PubMed FullText FullText_MUG

 

Scherzer, TM; Hofer, H; Staettermayer, AF; Rutter, K; Beinhardt, S; Steindl-Munda, P; Kerschner, H; Kessler, HH; Ferenci, P Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
J HEPATOL. 2011; 54(5): 866-871. Doi: 10.1016/j.jhep.2010.08.024
Web of Science PubMed FullText FullText_MUG

 

Scherzer, TM; Stättermayer, AF; Strasser, M; Laferl, H; Maieron, A; Stauber, R; Datz, C; Dulic-Lakovic, E; Steindl-Munda, P; Hofer, H; Ferenci, P Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
HEPATOLOGY. 2011; 54(5): 1518-1526. Doi: 10.1002/hep.24546 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Stättermayer, AF; Stauber, R; Hofer, H; Rutter, K; Beinhardt, S; Scherzer, TM; Zinober, K; Datz, C; Maieron, A; Dulic-Lakovic, E; Kessler, HH; Steindl-Munda, P; Strasser, M; Krall, C; Ferenci, P Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C.
Clin Gastroenterol Hepatol. 2011; 9(4): 344-350. Doi: 10.1016/j.cgh.2010.07.019
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2010

Bodlaj, G; Hubmann, R; Saleh, K; Stojakovic, T; Biesenbach, G; Berg, J Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.
World J Gastroenterol. 2010; 16(19): 2407-2410. Doi: 10.3748/wjg.v16.i19.2407 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hofer, H; Donnerer, J; Sator, K; Staufer, K; Scherzer, TM; Dejaco, C; Sator, M; Kessler, H; Ferenci, P Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.
J Hepatol. 2010; 52(6): 812-816. Doi: 10.1016/j.jhep.2009.12.039
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Rothenhäusler, HB; Scherr, M; Putz-Bankuti, C; Kapper, A; Stepan, A; Baranyi, A; Haas-Krammer, A; Haas, B; Stauber, R The relationship between emotional distress, cognitive performance and health - related quality of life in patients with hepatitis C prior to antiviral treatment.
Fortschr Neurol Psychiatr. 2009; 77(8): 457-463. Doi: 10.1055/s-0028-1109574
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Donnerer, J; Grahovac, M; Stelzl, E; Kessler, HH; Bankuti, C; Stadlbauer, V; Stauber, RE Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
PHARMACOLOGY. 2006; 76(3): 136-140. Doi: 10.1159/000090942
Web of Science PubMed FullText FullText_MUG

 

Ferenci, P; Formann, E; Laferl, H; Gschwantler, M; Hackl, F; Brunner, H; Hubmann, R; Datz, C; Stauber, R; Steindl-Munda, P; Kessler, HH; Klingler, A; Gangl, A; Austrian Hepatitis Study Group Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
J HEPATOL. 2006; 44(2): 275-282. Doi: 10.1016/j.jhep.2005.09.015
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Stauber, RE; Stadlbauer, V Novel approaches for therapy of chronic hepatitis C.
J CLIN VIROL. 2006; 36(2): 87-94. Doi: 10.1016/j.jcv.2006.02.003
Web of Science PubMed FullText FullText_MUG

 

2004

Lahousen, T; Hegenbarth, K; Ille, R; Lipp, RW; Krause, R; Little, RR; Schnedl, WJ Determination of glycated hemoglobin in patients with advanced liver disease.
World J Gastroenterol. 2004; 10(15):2284-2286 Doi: 10.3748/wjg.v10.i15.2284 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stauber, RE; Hofer, H; Hackl, F; Schütze, K; Datz, C; Hegenbarth, K; Jessner, W; Steindl-Munda, P; Peter, F; Austrian Hepatitis Study Group Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
WIEN KLIN WOCHENSCHR. 2004; 116(15-16): 530-535. Doi: 10.1007/BF03217706
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2003

Jessner, W; Stauber, R; Hackl, F; Datz, C; Watkins-Riedel, T; Hofer, H; Gangl, A; Kessler, H; Ferenci, P Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
J Viral Hepat. 2003; 10(1):37-42 Doi: 10.1046%2Fj.1365-2893.2003.00396.x
Web of Science PubMed FullText FullText_MUG

 

Metzler, H Hepatitis C. The point of view of a clinical anaesthetist and intensive care specialist
Anaesthesist. 2003; 52(5):453-455 Doi: 10.1007/s00101-003-0491-1
Web of Science PubMed FullText FullText_MUG

 

2002

Constantini, PK; Wawrzynowicz-Syczewska, M; Clare, M; Boron-Kaczmarska, A; McFarlane, IG; Cramp, ME; Donaldson, PT Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy.
Liver. 2002; 22(5):404-412 Doi: 10.1034/j.1600-0676.2002.01553.x
Web of Science PubMed FullText FullText_MUG

 

2001

Ferenci, P; Brunner, H; Nachbaur, K; Datz, C; Gschwantler, M; Hofer, H; Stauber, R; Hackl, F; Jessner, W; Rosenbeiger, M; Munda-Steindl, P; Hegenbarth, K; Gangl, A; Vogel, W; Australian Hepatitis Study Group Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Hepatology. 2001; 34(5):1006-1011 Doi: 10.1053/jhep.2001.28706 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ferenci, P; Stauber, R; Steindl-Munda, P; Gschwantler, M; Fickert, P; Datz, C; Müller, C; Hackl, F; Rainer, W; Watkins-Riedel, T; Lin, W; Krejs, GJ; Gangl, A; Austrian Hepatitis Study Group Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Eur J Gastroenterol Hepatol. 2001; 13(6):699-705 Doi: 10.1097/00042737-200106000-00014
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Hegenbarth, K; Maurer, U; Kroisel, PM; Fickert, P; Trauner, M; Stauber, RE No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.
Am J Gastroenterol. 2001; 96(7):2286-2287 Doi: 10.1111/j.1572-0241.2001.03997.x (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2000

Lackner, H; Moser, A; Deutsch, J; Kessler, HH; Benesch, M; Kerbl, R; Schwinger, W; Dornbusch, HJ; Preisegger, KH; Urban, C Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy.
Pediatrics. 2000; 106(4):E53-E53 Doi: 10.1542/peds.106.4.e53 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1999

Ferenci, P; Stauber, R; Steindl-Munda, P; Gschwantler, M; Fickert, P; Datz, C; Müller, C; Hackl, F; Rainer, W; Watkins-Riedel, T; Lin, W Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
J Viral Hepat. 1999; 6 Suppl 1(7):53-58 Doi: 10.1046/j.1365-2893.1999.00005.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kessler, HH; Pierer, K; Santner, BI; Vellimedu, SK; Stelzl, E; Marth, E; Fickert, P; Stauber, RE Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
J Hum Virol. 1999; 1(5):314-319
PubMed

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum